GILD Stock Chart & Fundamental Analysis

Interactive Chart

About Gilead Sciences, Inc.

Name

Gilead Sciences, Inc.

CEO

Daniel O'Day

Website

www.gilead.com

Industry

Healthcare

Year Founded

1987

Employees

17,600

Gilead Sciences, Inc. is a biopharmaceutical company focused on antiviral and immunology therapies that are used by health systems around the world. The portfolio spans treatments for infectious diseases and serious chronic conditions, with programs that move from discovery to access through a single, repeatable pathway. Research groups work with clinical partners to translate science into medicines that can be delivered at scale, while medical affairs teams support appropriate use in real settings. Manufacturing and quality systems favor reliability over showy launches, so supply stays steady as demand shifts between regions. The company operates across the Americas, Europe, and Asia with a consistent emphasis on safety, evidence, and responsible distribution. In coverage of large-cap biotech, Gilead Sciences, Inc. stock (GILD) often marks investor interest in therapeutic franchises that combine established use with ongoing research.

Analyst Ratings

Consensus Recommendation

Buy13

Hold7

Sell1

Fundamentals & Financials

Revenue (TTM)

$29.4B

Net Income (TTM)

$8.5B

EPS (TTM)

$6.85

ROA (TTM)

14.42%

Current Ratio

1.68

Dividend Yield

0.097%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q4 2025	Q3 2025	Q2 2025
Revenue	$7,925M	$7,769M	$7,081M
Cost of Sales	$1,043M	$1,569M	$1,501M
Gross Profit	$6,882M	$6,200M	$5,580M
Operating Income	$2,964M	$3,327M	$2,474M
Net Income	$2,183M	$3,052M	$1,960M
EPS	$1.76	$2.46	$1.57

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

Gilead Sciences, Inc.'s Technical Indicators Summary

GILD is showing a bullish technical profile as its current price comfortably exceeds key moving averages across short, medium, and long-term horizons, indicating an established upward trend. Momentum indicators such as the MACD and Momentum (10) reinforce this positive bias, while the RSI and CCI remain neutral, suggesting room for further movement without overextension. Although the ADX points to moderate trend strength, the steady on-balance volume supports sustained buying interest. Volatility is relatively stable, with the ATR reflecting modest price fluctuation. Overall, the technical signals align to depict a constructive environment for GILD, highlighted by strong moving average support and positive momentum. The technical takeaway: GILD maintains a firm bullish stance with healthy momentum and volume backing.

Buy

13 signals

Neutral

7 signals

Sell

1 signal

Overall: Bullish62% Bullish signals

Indicator	Value	Signal	Explanation
RSI (14)	54.82	Neutral	RSI (54.82) is neutral.
Stochastic %K (14, 3, 3)	73.90	Neutral	Stochastic (73.90) is neutral.
CCI (20)	52.74	Neutral	CCI (52.74) is neutral.
WPR (14)	-4.29	Sell	Williams %R (-4.29) > -20, indicating overbought.
Momentum (10)	3.31	Buy	Momentum (3.31) is positive.
MFI	42.92	Neutral	MFI (42.92) is neutral.
MACD Level (12, 26)	0.05	Buy	Confirmed uptrend: MACD (0.05) is positive and above its signal line (-0.10).
Bollinger Bands	$119.05 - $126.78	Neutral	Price is within the bands.
ATR (14)	$3.20 (2.56%)	Neutral	Moderate Volatility (2.56%).
ADX (14)	13.11	Neutral	Weak or consolidating trend (ADX < 25). ADX(13.11), +DI(16.56), -DI(18.18)
OBV	218,774,800	Buy	Bullish volume pressure: OBV is above its 20-day SMA. OBV(218,774,800), 20D-SMA-OBV(208,342,665)
Simple Moving Averages	$114.41 - $123.13(5 indicators)	Buy	The current price of $124.91 is above all key SMA levels—10, 20, 50, 100, and 200 periods—indicating a strong bullish trend across short to long-term moving averages.
Exponential Moving Averages	$115.20 - $122.69(5 indicators)	Buy	Price at $124.91 is above all key EMAs (10, 20, 50, 100, 200), indicating a strong bullish trend across short to long-term periods.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

The day concluded with GILD hovering close to the prior 154.98, with the tiny 0.187% gap leaving it around 155.27. The session wrapped with neutral sector performance (-0.16%), offering little macro push or pull. GILD moves amid limited headlines despite promising HIV treatment and prevention data announcements.

Price Change

from $154.98 close

+$0.29

Trading Volume

Below avg (8.5M)

5.7M

vs S&P 500 Today

Moderate Outperformance

+0.14%

52-Week Position

Near highs

96.8%